188 related articles for article (PubMed ID: 19755656)
1. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.
Perkins KA; Lerman C; Mercincavage M; Fonte CA; Briski JL
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2608-12. PubMed ID: 19755656
[TBL] [Abstract][Full Text] [Related]
2. Predicting smoking cessation. Who will quit with and without the nicotine patch.
Kenford SL; Fiore MC; Jorenby DE; Smith SS; Wetter D; Baker TB
JAMA; 1994 Feb; 271(8):589-94. PubMed ID: 8301790
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.
Conti DV; Lee W; Li D; Liu J; Van Den Berg D; Thomas PD; Bergen AW; Swan GE; Tyndale RF; Benowitz NL; Lerman C;
Hum Mol Genet; 2008 Sep; 17(18):2834-48. PubMed ID: 18593715
[TBL] [Abstract][Full Text] [Related]
4. Anxiety Sensitivity and Distress Tolerance in Smokers: Relations With Tobacco Dependence, Withdrawal, and Quitting Success†.
Schlam TR; Baker TB; Smith SS; Cook JW; Piper ME
Nicotine Tob Res; 2020 Jan; 22(1):58-65. PubMed ID: 31056710
[TBL] [Abstract][Full Text] [Related]
5. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.
Ferguson SG; Gitchell JG; Shiffman S; Sembower MA
Clin Ther; 2009 Sep; 31(9):1957-65. PubMed ID: 19843485
[TBL] [Abstract][Full Text] [Related]
6. Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.
Tomaz PRX; Santos JR; Scholz J; Abe TO; Gaya PV; Negrão AB; Krieger JE; Pereira AC; Santos PCJL
BMC Med Genet; 2018 Apr; 19(1):55. PubMed ID: 29621993
[TBL] [Abstract][Full Text] [Related]
7. Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial.
Zawertailo L; Hendershot CS; Tyndale RF; Le Foll B; Samokhvalov AV; Thorpe KE; Pipe A; Reid RD; Selby P
Trials; 2020 Jun; 21(1):592. PubMed ID: 32600406
[TBL] [Abstract][Full Text] [Related]
8. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial.
Schuurmans MM; Diacon AH; van Biljon X; Bolliger CT
Addiction; 2004 May; 99(5):634-40. PubMed ID: 15078238
[TBL] [Abstract][Full Text] [Related]
9. Mediators of the effect of nicotine pre-treatment on quitting smoking.
Hajek P; Lewis S; Munafo M; Lindson N; Coleman T; Aveyard P;
Addiction; 2018 Dec; 113(12):2280-2289. PubMed ID: 30066385
[TBL] [Abstract][Full Text] [Related]
10. Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods.
Przulj D; Wehbe L; McRobbie H; Hajek P
Addiction; 2019 Mar; 114(3):515-522. PubMed ID: 30370685
[TBL] [Abstract][Full Text] [Related]
11. Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.
Murphy CM; MacKillop J; Martin RA; Tidey JW; Colby SM; Rohsenow DJ
Psychopharmacology (Berl); 2017 Aug; 234(16):2443-2452. PubMed ID: 28500373
[TBL] [Abstract][Full Text] [Related]
12. Effects of nicotine versus placebo e-cigarette use on symptom relief during initial tobacco abstinence.
Perkins KA; Karelitz JL; Michael VC
Exp Clin Psychopharmacol; 2017 Aug; 25(4):249-254. PubMed ID: 28650184
[TBL] [Abstract][Full Text] [Related]
13. Supplemental nicotine preloading for smoking cessation in posttraumatic stress disorder: Results from a randomized controlled trial.
Dennis PA; Kimbrel NA; Dedert EA; Beckham JC; Dennis MF; Calhoun PS
Addict Behav; 2016 Aug; 59():24-9. PubMed ID: 27046670
[TBL] [Abstract][Full Text] [Related]
14. Nicotine patch therapy prior to quitting smoking: a meta-analysis.
Shiffman S; Ferguson SG
Addiction; 2008 Apr; 103(4):557-63. PubMed ID: 18339101
[TBL] [Abstract][Full Text] [Related]
15. Nicotine replacement therapy for smoking cessation.
Stead LF; Perera R; Bullen C; Mant D; Hartmann-Boyce J; Cahill K; Lancaster T
Cochrane Database Syst Rev; 2012 Nov; 11():CD000146. PubMed ID: 23152200
[TBL] [Abstract][Full Text] [Related]
16. Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region.
Sarginson JE; Killen JD; Lazzeroni LC; Fortmann SP; Ryan HS; Ameli N; Schatzberg AF; Murphy GM
Nicotine Tob Res; 2015 Sep; 17(9):1126-33. PubMed ID: 25572450
[TBL] [Abstract][Full Text] [Related]
17. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.
Rose JE; Herskovic JE; Behm FM; Westman EC
Nicotine Tob Res; 2009 Sep; 11(9):1067-75. PubMed ID: 19567826
[TBL] [Abstract][Full Text] [Related]
18. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation.
Caldwell BO; Adamson SJ; Crane J
Nicotine Tob Res; 2014 Oct; 16(10):1356-64. PubMed ID: 24872027
[TBL] [Abstract][Full Text] [Related]
19. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group.
Daughton D; Susman J; Sitorius M; Belenky S; Millatmal T; Nowak R; Patil K; Rennard SI
Arch Fam Med; 1998; 7(5):425-30. PubMed ID: 9755734
[TBL] [Abstract][Full Text] [Related]
20. Nicotine replacement therapy for smoking cessation.
Stead LF; Perera R; Bullen C; Mant D; Lancaster T
Cochrane Database Syst Rev; 2008 Jan; (1):CD000146. PubMed ID: 18253970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
